These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination. Wolfs TF; Nara PL; Goudsmit J Chem Immunol; 1993; 56():1-33. PubMed ID: 8383980 [No Abstract] [Full Text] [Related]
3. Assessment of HIV-1 antigenic diversification using serum as sample source. Goudsmit J; Zwart G; Wolfs T AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1473. PubMed ID: 1466985 [No Abstract] [Full Text] [Related]
4. HIV-1 primary infection in two pairs of patients: difference in variants transmitted and clinical follow-up. Innocenti-Francillard P; Brengel-Pesce K; Morand P; Ounanian-Paraz A; Leclercq P; Gruters R; Seigneurin JM AIDS; 1997 Mar; 11(4):539-42. PubMed ID: 9084806 [No Abstract] [Full Text] [Related]
5. Distribution of linear antigenic epitopes on GP120 encoded in sibling clones of novel New York HIV-1 subtype B isolates. Riley JP; Pestano GA; Harewood K; Alfred LJ; Guyden J; Boto WM Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S83-91. PubMed ID: 8574151 [TBL] [Abstract][Full Text] [Related]
6. Chimeric synthetic peptide as antigen for immunodiagnosis of HIV-1 infection. Hernández M; Pozo L; Gómez I; Melchor A Biochem Biophys Res Commun; 2000 May; 272(1):259-62. PubMed ID: 10872836 [TBL] [Abstract][Full Text] [Related]
7. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. Korber B; Wolinsky S; Haynes B; Kunstman K; Levy R; Furtado M; Otto P; Myers G AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1461-5. PubMed ID: 1281659 [No Abstract] [Full Text] [Related]
8. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail. Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291 [No Abstract] [Full Text] [Related]
9. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses. Hewer R; Meyer D Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588 [TBL] [Abstract][Full Text] [Related]
10. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope. Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580 [TBL] [Abstract][Full Text] [Related]
11. B cell antigenic site mapping of HIV-1 glycoproteins. Neurath AR Chem Immunol; 1993; 56():34-60. PubMed ID: 8452653 [No Abstract] [Full Text] [Related]
12. Molecular approaches to AIDS vaccine development using baculovirus expression vectors. Kang CY Methods Mol Biol; 1995; 39():295-315. PubMed ID: 7542523 [No Abstract] [Full Text] [Related]
13. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy. Liu Z; Chen YH J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538 [TBL] [Abstract][Full Text] [Related]
15. [A functional model of the central epitope of the V3 loop of HIV-1 gp120 when complexed with antibodies]. Shchelkanov MIu; Iaroslavtseva NG; Emel'ianov AV; Sakhuriia IB; Abélian AV; Verevochkin SV; Kozlov AP; Karamov EV Mol Biol (Mosk); 1998; 32(6):1062-74. PubMed ID: 9929887 [No Abstract] [Full Text] [Related]
16. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity. Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888 [TBL] [Abstract][Full Text] [Related]
17. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425 [No Abstract] [Full Text] [Related]
18. Significant genetic and antigenic variability within the env gene of systemic human immunodeficiency virus type 1 group O populations during the natural course of a heterosexual infection: a pilot study. Andréoletti L; Réveil B; Moret H; Brodard V; Philbert F; Tabary T; Cohen JH J Clin Microbiol; 2007 Apr; 45(4):1319-21. PubMed ID: 17267630 [TBL] [Abstract][Full Text] [Related]
20. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]